C Ray Therapeutics (Chengdu) Co., Ltd.

Chengdu, China

Overview

C Ray Therapeutics (Chengdu) Co., Ltd. is a pioneering biotechnology company focused on the development of cutting-edge therapies in the field of vision restoration and ocular diseases. With a dedication to innovative research and a robust pipeline, the company aims to address significant unmet medical needs.

Therapeutic areas

OphthalmologyVision RestorationOcular Diseases

API / Drug Master Files

C Ray Therapeutics (Chengdu) Co., Ltd. holds 1 active (1 total) FDA Type II Drug Master File — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

  • COPPER [64CU] CHLORIDE FOR RADIOLABELLINGActive2026-01-30

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to C Ray Therapeutics (Chengdu) Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.

Related companies

Lambdavision, Inc.
United States
Remegen Co., Ltd.
China
Shanghai Henlius Biotech, Inc.
China
Wuhan Yzy Biopharma Co., Ltd.
China
Aequus Pharmaceuticals Inc.
Canada
Ajanta Pharma Limited
India
Akorn Operating Company LLC
United States
Akorn, Inc.
United States

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.

Start free trialBook a demo